Pharma splits: AstraZeneca soars, Novartis stumbles

🌅 Today's Morning Call

S&P Futures 7,703.25 ▼ -18.75 (-0.24%)	Nasdaq Futures 29,589.25 ▲ +24.00 (+0.08%)	Dow Futures 53,034.00 ▼ -406.00 (-0.76%)
10Y Treasury 4.78% ▲ +0.02%	US Dollar 98.97 ▼ -0.19 (-0.20%)	Bitcoin $78,273 ▼ -$819 (-1.04%)

Data as of 8:07 AM ET

Good morning! Happy Tuesday. Markets are shaking off the long weekend with a decidedly mixed open on tap, and the real drama is playing out in the pharma aisle where trial results are splitting winners from losers. Let's break down what matters today.

👀 What to Watch Today

First full trading day after Labor Day, and futures are sending crossed signals. S&P 500 futures sit at 7,703.25, down 0.24%, while Nasdaq futures nudge higher at 29,589.25, up 0.08%. The Dow is the laggard, off 0.76% as blue chips feel the pressure.

Keep one eye on Treasuries. The 10-year yield ticked up to 4.78% and the 5-year climbed to 4.55%, a subtle reminder that rate sensitivity is still in play. The dollar index eased to 98.97, giving multinationals a small tailwind.

Biotech is today's main event. AstraZeneca (AZN), Bristol Myers (BMY), Roivant (ROIV), and Novartis (NVS) all have fresh trial data moving shares. Watch how clinical results translate into sector rotation once the bell rings.

Your Phone Is Smarter Than Your Inbox

Not every market move can wait. Our text alerts deliver the ones that can't. One short alert, straight to your phone, when something is worth seeing now. No fluff. No noise. No charge.

Text Me the Alerts

Trump’s stock disclosures [ad]

🌏 Overnight Recap

Global markets traded on a cautious footing overnight as investors returned from the long holiday weekend. Asian equities finished mixed, with Japan's Nikkei drifting lower on a firmer yen while Chinese benchmarks caught a modest bid on renewed hopes for policy support. European bourses opened tentatively, dragged by weakness in industrials even as healthcare names commanded attention on the back of dueling clinical data.

The backdrop is a market still recalibrating for rates. The 10-year Treasury yield edged up to 4.78% and the 5-year firmed to 4.55%, keeping the pressure on rate-sensitive corners of the tape. The dollar index softened to 98.97, offering a slight cushion to exporters and multinationals. With no major overnight catalyst to force conviction either way, traders are looking to the U.S. open and pharma headlines to set the tone.

23,281 stocks. Only ONE survived. [ad]

"Second Wave" Hitting Iran Soon? Wall Street Issues Warning

Goldman Sachs and Morgan Stanley are warning of a quiet domestic threat that could keep your portfolio in the red for 10 years or more. It has nothing to do with Iran. A former U.S. Air Force nuclear missile coder built an AI that can sidestep surprise crashes and potentially triple your portfolio in 12 months. No options, no crypto, no exotic plays.

See where AI believes Nvidia closes next session

📊 Pre-Market Movers

AstraZeneca (AZN) is the standout to the upside, rallying in pre-market trade after encouraging clinical trial results reignited enthusiasm for its pipeline. The move is lifting sentiment across parts of the biotech complex.

On the other side of the ledger, Novartis (NVS) is stumbling as its own trial readout disappointed, a sharp reminder that binary clinical events cut both ways. Bristol Myers Squibb (BMY) and Roivant (ROIV) are also in motion on fresh data, making the pharma space the most active battleground of the morning.

Outside of healthcare, Alphabet (GOOGL) is drawing interest on continued momentum behind its AI initiatives, a narrative that keeps investors leaning into the mega-cap tech trade even as the broader Dow futures signal caution.

Read this or regret it forever [ad]

🔍 Today's Watchlist

AstraZeneca (AZN): Shares are surging pre-market on strong clinical trial results. Watch for follow-through buying and whether the enthusiasm spills over into peer biotech names once regular trading begins.
Novartis (NVS): Under pressure after a disappointing trial readout. Monitor for downside continuation or a bargain-hunting bounce, and gauge how the miss reshapes competitive positioning against AstraZeneca.
Bristol Myers Squibb (BMY): In focus on fresh trial data. This is a key name for reading whether the day's pharma action is stock-specific or a broader sector re-rating.
Roivant Sciences (ROIV): Moving on clinical developments and worth watching as a higher-beta biotech play. Expect outsized swings that can telegraph broader risk appetite in the space.
Alphabet (GOOGL): Drawing attention on its ongoing AI push. Keep it on the radar as a barometer for mega-cap tech sentiment, especially with Nasdaq futures pointing modestly higher.

Elon Musk Just Said 8 Words That Should TERRIFY Every Investor on Wall Street

"The cost of everything will drop to NOTHING." That's what Musk told a room full of stunned executives. Most people laughed. One man didn't. A 41-year stock market legend - the SAME man who bought Apple at $1... called NVIDIA at $1.10... both split adjusted says Musk is right. And he's identified a handful of companies that could EXPLODE as this "deflation bomb" detonates across the economy.

For the full story, click here.

🎯 The Morning Playbook

The playbook today is all about separating signal from noise in the pharma tape. Trial-driven moves like those in AstraZeneca and Novartis tend to spark sector rotation, so watch whether money flows into the biotech winners or simply rotates out of the losers. A clean divergence would suggest stock-specific reactions rather than a broad sector call.

Keep the rate picture front and center. With the 10-year at 4.78%, any further backup in yields could pressure growth and momentum names, while a stabilization would give the Nasdaq room to extend its slight pre-market edge. The Dow's underperformance, off 0.76% in futures, hints that cyclical and blue-chip names may need a catalyst to catch up.

Discipline matters after a holiday-shortened week. Volumes can be thin early, exaggerating moves, so let the first hour establish direction before committing to conviction trades.

Did you see the WSJ on 8-9? [ad]

📰 Further Reading

The world's #2 gold miner is running on fumes [it has to buy] (Ad)

Barrick, the second-biggest gold miner on earth, has watched production collapse from two million ounces to 719,000. That is not a dip. That is a company burning through its own future. Gold majors sitting on record cash flows have one move left: buy the best junior assets at whatever premium it tak...

Get the top three buyout targets now

The Pentagon is Desperate (Ad)

Russia and China have hypersonic missiles moving so fast our radar cannot track them. The Pentagon admits we are in third place. So the government found a tiny Florida company under $5 a share to solve the crisis. Lockheed Martin and the Air Force are already paying them. A major licensing milestone...

Click Here to See the Hypersonic Backdoor and Get the Name of the Company

#1 Stock to Own as Trump Launches Historic Mission Backing "Medical AI" (Ad)

In the biggest federal push since the Apollo program that landed on the Moon... Trump is now pouring the full support of the federal government into a new type of AI that could soon be worth 500 times more than ChatGPT. It works 10,000 times faster than human PhDs... and Elon Musk calls the underlyi...

Click here to learn about the #1 stock to own as this new AI goes live.